Antiseizure adverse drug reaction and associated factors among epileptic patients at Jimma Medical Center: a prospective observational study.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Anticonvulsants*/adverse effects ; Epilepsy*/drug therapy ; Drug-Related Side Effects and Adverse Reactions*/epidemiology; Humans ; Female ; Male ; Adult ; Prospective Studies ; Ethiopia/epidemiology ; Adolescent ; Young Adult ; Middle Aged ; Risk Factors ; Prevalence

A growing body of evidence suggests that adverse drug reactions (ADRs) are a major cause of morbidity and mortality in the healthcare system. Fifteen to twenty-five percent of patients with epilepsy discontinued antiseizure drugs (ASDs) within 6 months of therapy owing to intolerable adverse drug reactions. In Ethiopia, the prevalence of antiseizure adverse drug reactions and associated factors was not extensively conducted in advanced settings like Jimma Medical Centers. Hence, the objective of this study is to assess patterns of adverse drug reactions and associated factors among ambulatory epileptic patients at tertiary hospitals in Ethiopia. A hospital-based prospective observational study was spanned for 1 year. Two hundred ninety patients were consecutively recruited into the study from all epileptic patients attending the ambulatory clinic. Relevant data were collected through patient interviews and medical chart reviews. The causality assessment was done by using the Naranjo Probability Scale. Epi-Data manager version 4.6.0.4 was used for data entry and statistical analysis was performed by Statistical Package for Social Science version 25.0 (SPSS). Stepwise backward logistic regression analysis was done to identify factors that increase the risk of antiseizure adverse drug reactions. The mean (± SD) age of the participants were 29.91(± 11.26) years. The overall prevalence of ADR was 33.8% (95% CI 29.2-39.9%). A total of 110 adverse drug reactions were identified among 98 patients with an average of 1.12 per patient. ADRs were frequently reported with phenobarbital (52.04%) and phenytoin (34.70%). The commonly identified adverse drug reactions were epigastric pain (27.55%) and central nervous system drowsiness (23.46%). Comorbidity (AOR = 5.91, 95% CI (2.14-16.32), seizure-free period of fewer than 2 years (AOR = 1.94, 95% CI (1.18-3.19), and polytherapy (AOR = 1.35, 95% CI (1.80-2.26) were significantly associated with adverse drug reactions. This trial had a comparatively high percentage of adverse medication reactions. Adverse medication reactions were more common in patients with polytherapy, comorbidities, and seizure-free durations less than two years. Therefore, medical practitioners should advise patients who exhibit these traits on how to reduce or avoid bad drug responses or provide comfort in the event of small incidents.
(© 2024. The Author(s).)

Drugs. 2006;66(14):1817-29. (PMID: 17040113)
PLoS One. 2017 Feb 6;12(2):e0171470. (PMID: 28166274)
Epilepsy Behav. 2023 Mar;140:109089. (PMID: 36696732)
Lancet Neurol. 2012 Sep;11(9):792-802. (PMID: 22832500)
BMC Pharmacol Toxicol. 2020 Dec 10;21(1):87. (PMID: 33303036)
Neurol Res Int. 2018 Nov 25;2018:8490639. (PMID: 30595918)
Nihon Rinsho. 2014 May;72(5):908-19. (PMID: 24912294)
Epilepsia. 2014 Apr;55(4):475-82. (PMID: 24730690)
Curr Drug Saf. 2019;14(3):217-224. (PMID: 30854975)
PLoS One. 2023 Feb 24;18(2):e0282096. (PMID: 36827307)
SAGE Open Med. 2018 May 04;6:2050312118772471. (PMID: 29760918)
Intern Emerg Med. 2022 Aug;17(5):1453-1462. (PMID: 35129789)
Front Pharmacol. 2018 Apr 11;9:350. (PMID: 29695966)
Pharmacol Res Perspect. 2017 Mar 24;5(2):e00302. (PMID: 28357128)
Neurology. 2014 Nov 18;83(21):1968-77. (PMID: 25339211)
PLoS One. 2018 Oct 11;13(10):e0205426. (PMID: 30308067)
Int J Environ Res Public Health. 2022 Apr 08;19(8):. (PMID: 35457375)
Seizure. 2009 Jun;18(5):327-31. (PMID: 19110447)
Lancet Neurol. 2016 Jan;15(1):106-15. (PMID: 26549780)
Pharmaceuticals (Basel). 2010 Jul 26;3(8):2362-2379. (PMID: 27713357)
Indian J Pediatr. 2022 Jan;89(1):74-76. (PMID: 34591273)
J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S73-7. (PMID: 24347988)
PLoS One. 2022 Apr 28;17(4):e0267673. (PMID: 35482756)
Epilepsy Behav. 2020 Apr;105:106947. (PMID: 32109858)
JAMA Neurol. 2020 May 1;77(5):574-581. (PMID: 32091535)
Paediatr Drugs. 2021 Jan;23(1):55-73. (PMID: 33230678)
BMC Pharmacol Toxicol. 2019 Jan 14;20(1):7. (PMID: 30642405)
N Engl J Med. 2000 Feb 3;342(5):314-9. (PMID: 10660394)
Saudi Pharm J. 2014 Apr;22(2):83-94. (PMID: 24648818)

Keywords: Adverse drug reactions; Antiseizure drugs; Epilepsy; Ethiopia

Date Created: 20240521 Date Completed: 20240521 Latest Revision: 20240524

20240524

PMC11109189

10.1038/s41598-024-61393-9

38773234